<DOC>
	<DOCNO>NCT00042094</DOCNO>
	<brief_summary>This study evaluate safety efficacy Dryvax速 new cell-cultured vaccine ( CCSV ) comparative fashion . Across 3 cohort , 150 vaccinia-naive volunteer randomly assign receive either CCSV ( 100 volunteer ) Dryvax速 ( 50 volunteer ) blind fashion . Subjects follow closely 6 month subgroup volunteer follow 3 year order evaluate duration immunity follow vaccination . Another cohort enroll 100 vaccinia-experienced volunteer randomly assign receive either CCSV ( 50 volunteer ) Dryvax速 ( 50 volunteer ) sub group follow 3 year . A fifth cohort enroll 100 vaccinia-naive volunteer randomly assign receive different dilution CCSV ( 1:1 , 1:5 , 1:25 , 1:50 ) .</brief_summary>
	<brief_title>Study Reactogenicity , Safety , Immunogenicity , Pock Lesion Formation Cell-Cultured Smallpox Vaccine Compared Dryvax速</brief_title>
	<detailed_description />
	<mesh_term>Smallpox</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Have never receive smallpox vaccine previously receive experimental smallpox vectored vaccine ( vaccinianaive cohort ) Have previously vaccinate within last 10 year ( vacciniaexperienced cohort ) Must agree blood sample bank future research test Have participate clinical trial use investigational product within past month No current past history exfoliative skin problem Not regular contact child 3 year age scab site vaccination fall ( around 21 day 3 week vaccination ) Do positive test HIV virus , hepatitis C virus , hepatitis B surface antigen Are health care worker care newborn , patient immunocompromised skin adversely alter Will engage direct patient care immunization scab fall ( around 21 day 3 week vaccination ) health care worker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Smallpox</keyword>
	<keyword>Smallpox Vaccine</keyword>
	<keyword>Vaccinia</keyword>
</DOC>